Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Anti-TNFα alters the natural history of experimental Crohn's disease in rats when begun early, but not late, in disease.

Schmiedlin-Ren P, Reingold LJ, Broxson CS, Rittershaus AC, Brudi JS, Adler J, Owens SR, Zimmermann EM.

Am J Physiol Gastrointest Liver Physiol. 2016 Oct 1;311(4):G688-G698. doi: 10.1152/ajpgi.00216.2015. Epub 2016 Aug 25.

2.

Development of a peptidoglycan-polysaccharide murine model of Crohn's disease: effect of genetic background.

Reingold L, Rahal K, Schmiedlin-Ren P, Rittershaus AC, Bender D, Owens SR, Adler J, Zimmermann EM.

Inflamm Bowel Dis. 2013 May;19(6):1238-44. doi: 10.1097/MIB.0b013e31828132b4.

PMID:
23619717
3.

Anti-tumor necrosis factor α prevents bowel fibrosis assessed by messenger RNA, histology, and magnetization transfer MRI in rats with Crohn's disease.

Adler J, Rahal K, Swanson SD, Schmiedlin-Ren P, Rittershaus AC, Reingold LJ, Brudi JS, Shealy D, Cai A, McKenna BJ, Zimmermann EM.

Inflamm Bowel Dis. 2013 Mar-Apr;19(4):683-90. doi: 10.1097/MIB.0b013e3182802c32.

PMID:
23429466
4.

Resveratrol has antiinflammatory and antifibrotic effects in the peptidoglycan-polysaccharide rat model of Crohn's disease.

Rahal K, Schmiedlin-Ren P, Adler J, Dhanani M, Sultani V, Rittershaus AC, Reingold L, Zhu J, McKenna BJ, Christman GM, Zimmermann EM.

Inflamm Bowel Dis. 2012 Apr;18(4):613-23. doi: 10.1002/ibd.21843. Epub 2011 Aug 29.

5.

Resveratrol causes cell cycle arrest, decreased collagen synthesis, and apoptosis in rat intestinal smooth muscle cells.

Garcia P, Schmiedlin-Ren P, Mathias JS, Tang H, Christman GM, Zimmermann EM.

Am J Physiol Gastrointest Liver Physiol. 2012 Feb 1;302(3):G326-35. doi: 10.1152/ajpgi.00083.2011. Epub 2011 Nov 3.

6.

Magnetization transfer helps detect intestinal fibrosis in an animal model of Crohn disease.

Adler J, Swanson SD, Schmiedlin-Ren P, Higgins PD, Golembeski CP, Polydorides AD, McKenna BJ, Hussain HK, Verrot TM, Zimmermann EM.

Radiology. 2011 Apr;259(1):127-35. doi: 10.1148/radiol.10091648. Epub 2011 Jan 28.

7.
8.

Restituting intestinal epithelial cells exhibit increased transducibility by adenoviral vectors.

Kesisoglou F, Schmiedlin-Ren P, Fleisher D, Roessler B, Zimmermann EM.

J Gene Med. 2006 Dec;8(12):1379-92.

9.

Chimeric Ad5 vectors expressing the short fiber of Ad41 show reduced affinity for human intestinal epithelium.

Kesisoglou F, Chamberlain JR, Schmiedlin-Ren P, Kaz A, Fleisher D, Roessler B, Zimmermann EM.

Mol Pharm. 2005 Nov-Dec;2(6):500-8.

PMID:
16323957
10.

Increased transduction of human intestinal epithelial cells by adenoviral vectors in inflammatory bowel disease.

Schmiedlin-Ren P, Kesisoglou F, Mapili JA, Sabek SE, Barnett JL, Chey WD, Roessler B, Zimmermann EM.

Inflamm Bowel Dis. 2005 May;11(5):464-72.

PMID:
15867586
11.

IGF-I increases IGFBP-5 and collagen alpha1(I) mRNAs by the MAPK pathway in rat intestinal smooth muscle cells.

Xin X, Hou YT, Li L, Schmiedlin-Ren P, Christman GM, Cheng HL, Bitar KN, Zimmermann EM.

Am J Physiol Gastrointest Liver Physiol. 2004 May;286(5):G777-83.

12.

Induction of CYP3A4 by 1 alpha,25-dihydroxyvitamin D3 is human cell line-specific and is unlikely to involve pregnane X receptor.

Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Watkins PB.

Drug Metab Dispos. 2001 Nov;29(11):1446-53.

PMID:
11602520
13.

First-pass midazolam metabolism catalyzed by 1alpha,25-dihydroxy vitamin D3-modified Caco-2 cell monolayers.

Fisher JM, Wrighton SA, Watkins PB, Schmiedlin-Ren P, Calamia JC, Shen DD, Kunze KL, Thummel KE.

J Pharmacol Exp Ther. 1999 May;289(2):1134-42.

PMID:
10215697
14.

Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole.

Paine MF, Schmiedlin-Ren P, Watkins PB.

Drug Metab Dispos. 1999 Mar;27(3):360-4.

PMID:
10064566
15.

Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins.

Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF, Watkins PB.

Drug Metab Dispos. 1997 Nov;25(11):1228-33.

PMID:
9351897
16.

Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.

Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB.

Clin Pharmacol Ther. 1997 Sep;62(3):248-60.

17.

Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3.

Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Lown KS, Watkins PB.

Mol Pharmacol. 1997 May;51(5):741-54.

PMID:
9145912
18.

Selective expression of CYP3A5 and not CYP3A4 in human blood.

Janardan SK, Lown KS, Schmiedlin-Ren P, Thummel KE, Watkins PB.

Pharmacogenetics. 1996 Oct;6(5):379-85.

PMID:
8946469
19.

CYP3A gene expression in human gut epithelium.

Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, Watkins PB.

Pharmacogenetics. 1994 Oct;4(5):247-59.

PMID:
7894497
20.

Aflatoxin B1-adduct formation in rat and human small bowel enterocytes.

Kolars JC, Benedict P, Schmiedlin-Ren P, Watkins PB.

Gastroenterology. 1994 Feb;106(2):433-9.

PMID:
8299909
21.

Cultured adult rat jejunal explants as a model for studying regulation of CYP3A.

Schmiedlin-Ren P, Benedict PE, Dobbins WO 3rd, Ghosh M, Kolars JC, Watkins PB.

Biochem Pharmacol. 1993 Sep 1;46(5):905-18.

22.

Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.

Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB.

J Clin Invest. 1992 Nov;90(5):1871-8.

23.

Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia.

Kolars JC, Schmiedlin-Ren P, Dobbins WO 3rd, Schuetz J, Wrighton SA, Watkins PB.

Gastroenterology. 1992 Apr;102(4 Pt 1):1186-98.

PMID:
1551527
24.

Cyclosporine metabolism by P450IIIA in rat enterocytes--another determinant of oral bioavailability?

Kolars JC, Stetson PL, Rush BD, Ruwart MJ, Schmiedlin-Ren P, Duell EA, Voorhees JJ, Watkins PB.

Transplantation. 1992 Mar;53(3):596-602.

PMID:
1549853

Supplemental Content

Loading ...
Support Center